Skip to content

Alnylam Pharmaceuticals

US · ALNY #627 by market cap Listed 1970
143.82 -4.00 -2.71%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    Alnylam Pharmaceuticals Is Maintained at Neutral by Cantor Fitzgerald
    Dow Jones · 2026/11/17
  • Company notice
    Alnylam Pharmaceuticals | SCHEDULE 13G: Others
    SEC · 2026/11/17
  • Company notice
    Alnylam Pharmaceuticals | SCHEDULE 13G/A: Others
    SEC · 2026/11/14
  • Rating change
    H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $455
    Market Newswire · 2026/11/12
  • Rating change
    Citi Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $250
    Market Newswire · 2026/11/10
  • Rating change
    Citi Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Cuts Target Price to $250
    Market Newswire · 2026/11/9
  • BMO Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $293
    Market Newswire · 2026/11/20
  • Rating change
    Cantor Fitzgerald Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Cuts Target Price to $290
    Market Newswire · 2026/11/7
  • H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Cuts Target Price to $250
    Market Newswire · 2026/11/17
  • Company notice
    Alnylam Pharmaceuticals | SCHEDULE 13G/A: Others
    SEC · 2026/11/14
  • Rating change
    Piper Sandler Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $410
    Market Newswire · 2026/11/10
  • Rating change
    Wells Fargo Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Cuts Target Price to $220
    Market Newswire · 2026/11/5
  • Rating change
    Alnylam Pharmaceuticals Is Maintained at Overweight by Barclays
    Dow Jones · 2026/11/3
  • J.P. Morgan Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Cuts Target Price to $254
    Market Newswire · 2026/11/18
  • Cantor Fitzgerald Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Cuts Target Price to $205
    Market Newswire · 2026/11/17
  • Company notice
    Alnylam Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Greenstreet Yvonne
    SEC · 2026/11/18
  • Rating change
    Alnylam Pharmaceuticals Price Target Cut to $380.00/Share From $450.00 by Barclays
    Dow Jones · 2026/11/3
  • Company notice
    Alnylam Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director SCHULMAN AMY W
    SEC · 2026/11/13
  • Rating change
    A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $292 to $455
    Market Newswire · 2026/11/6
  • Cantor Fitzgerald Maintains Neutral on Alnylam Pharmaceuticals, Lowers Price Target to $205
    Benzinga · 2026/11/17
  • H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $455
    Market Newswire · 2026/11/7
  • Rating change
    Alnylam Pharmaceuticals Cut to Hold From Buy by Truist Securities
    Dow Jones · 2026/11/2
  • Company notice
    Alnylam Pharmaceuticals | 8-K: Current report
    SEC · 2026/11/5
  • Company notice
    Alnylam Pharmaceuticals | 10-Q: Quarterly report
    SEC · 2026/10/29
  • Piper Sandler Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $410
    Market Newswire · 2026/11/5

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Alnylam Pharmaceuticals discussion 0 comments

Add a comment